Business Standard

Double-digit price erosion in the US generic market is getting arrested.

Double-digit price erosion in the US generic market is getting arrested.

After a poor run in 2022, Pharma and healthcare funds are up 22.4 per cent year-to-date. The fundamental reason behind this upsurge is the improving outlook of the US generic market, says Mr. Chirag Dagli, Fund Manager, DSP Mutual Fund. In an interview with Sanjay Kumar Singh, Associate Editor, Business Standard, he says that price erosion has got arrested, approvals for new drugs have started coming through, and supply disruptions in the US generic market will work to the advantage of Indian players. If you are contemplating an investment in a Pharma fund, do watch this interview for in-depth insights into the sector’s prospects.

Explore News